Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome

References

• Michalik L, Auwerx J, Berger JP, et al. International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev. 2006;58:726–741.
   PubMed Web of Science ®Google Scholar
• Nuclear Receptors Nomenclature Committee. A unified nomenclature system for the nuclear receptor superfamily. Cell. 1999;97:161–163.
   PubMed Web of Science ®Google Scholar
• Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000;405:421–424.
   PubMed Web of Science ®Google Scholar
• Mukherjee R, Jow L, Noonan D, et al. Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem Mol Biol. 1994;51:157–166.
   PubMed Web of Science ®Google Scholar
• Kliewer SA, Forman BM, Blumberg B, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA. 1994;91:7355–7359.
   PubMed Web of Science ®Google Scholar
• Braissant O, Foufelle F, Scotto C, et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996;137:354–366.
   PubMed Web of Science ®Google Scholar
• Keller H, Dreyer C, Medin J, et al. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA. 1993;90:2160–2164.
   PubMed Web of Science ®Google Scholar
• Kliewer SA, Umesono K, Noonan DJ, et al. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 1992;358:771–774.
   PubMed Web of Science ®Google Scholar
• Feige JN, Gelman L, Michalik L, et al. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res. 2006;45:120–159.
   PubMed Web of Science ®Google Scholar
• Wadosky KM, Willis MS. The story so far: post-translational regulation of peroxisome proliferator-activated receptors by ubiquitination and SUMOylation. Am J Physiol Heart Circ Physiol. 2012;302:H515–H526.
   PubMed Web of Science ®Google Scholar
• Pascual G, Fong AL, Ogawa S, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature. 2005;437:759–763.
   PubMed Web of Science ®Google Scholar
• Leuenberger N, Pradervand S, Wahli W. Sumoylated PPARalpha mediates sex-specific gene repression and protects the liver from estrogen-induced toxicity in mice. J Clin Invest. 2009;119:3138–3148.
   PubMed Web of Science ®Google Scholar
• Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999;20:649–688.
   PubMed Web of Science ®Google Scholar
• Lalloyer F, Staels B. Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol. 2010;30:894–899.
   PubMed Web of Science ®Google Scholar
• Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 2014;20:573–591.
   PubMed Web of Science ®Google Scholar
• Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab. 2012;23:205–215.
   PubMed Web of Science ®Google Scholar
• Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci. 2005;26:244–251.
   PubMed Web of Science ®Google Scholar
• Kersten S, Seydoux J, Peters JM, et al. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest. 1999;103:1489–1498.
   PubMed Web of Science ®Google Scholar
• Montagner A, Polizzi A, Fouche E, et al. Liver PPARalpha is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut. 2016;65:1202–1214.
   PubMed Web of Science ®Google Scholar
• Liu ZM, Hu M, Chan P, et al. Early investigational drugs targeting PPAR-alpha for the treatment of metabolic disease. Expert Opin Investig Drugs. 2015;24:611–621.
   PubMed Web of Science ®Google Scholar
• Zandbergen F, Plutzky J. PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta. 2007;1771:972–982.
   PubMed Web of Science ®Google Scholar
• Jackevicius CA, Tu JV, Ross JS, et al. Use of fibrates in the United States and Canada. JAMA. 2011;305:1217–1224.
   PubMed Web of Science ®Google Scholar
• Nadeau KJ, Ehlers LB, Aguirre LE, et al. Discordance between intramuscular triglyceride and insulin sensitivity in skeletal muscle of Zucker diabetic rats after treatment with fenofibrate and rosiglitazone. Diabetes Obes Metab. 2007;9:714–723.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Wolff DA, Huskin AL, et al. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care. 2007;30:1945–1951.
   PubMed Web of Science ®Google Scholar
• Schafer HL, Linz W, Falk E, et al. AVE8134, a novel potent PPARalpha agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats. Acta Pharmacol Sin. 2012;33:82–90.
   PubMed Web of Science ®Google Scholar
• Oshida K, Vasani N, Thomas RS, et al. Identification of modulators of the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) in a mouse liver gene expression compendium. PLoS One. 2015;10:e0112655.
   PubMed Web of Science ®Google Scholar
• Devchand PR, Keller H, Peters JM, et al. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature. 1996;384:39–43.
   PubMed Web of Science ®Google Scholar
• Rodriguez de Fonseca F, Navarro M, Gomez R, et al. An anorexic lipid mediator regulated by feeding. Nature. 2001;414:209–212.
   PubMed Web of Science ®Google Scholar
• Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. 2003;425:90–93.
   PubMed Web of Science ®Google Scholar
• Guzman M, Lo Verme J, Fu J, et al. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem. 2004;279:27849–27854.
   PubMed Web of Science ®Google Scholar
• Fu J, Oveisi F, Gaetani S, et al. Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology. 2005;48:1147–1153.
   PubMed Web of Science ®Google Scholar
• Deblon N, Veyrat-Durebex C, Bourgoin L, et al. Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats. PLoS One. 2011;6:e25565.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Jia Y. The effect of bioactive compounds in tea on lipid metabolism and obesity through regulation of peroxisome proliferator-activated receptors. Curr Opin Lipidol. 2015;26:3–9.
   PubMed Web of Science ®Google Scholar
• El Kochairi I, Montagner A, Rando G, et al. Beneficial effects of combinatorial micronutrition on body fat and atherosclerosis in mice. Cardiovasc Res. 2011;91:732–741.
   PubMed Web of Science ®Google Scholar
• Chen W, Lai Y, Wang L, et al. Astragalus polysaccharides repress myocardial lipotoxicity in a PPARalpha-dependent manner in vitro and in vivo in mice. J Diabetes Complications. 2015;29:164–175.
   PubMed Web of Science ®Google Scholar
• Xu SF, Jin T, Lu YF, et al. Effect of icariin on UDP-glucuronosyltransferases in mouse liver. Planta Med. 2014;80:387–392.
   PubMed Web of Science ®Google Scholar
• Zhang WP, Bai XJ, Zheng XP, et al. Icariin attenuates the enhanced prothrombotic state in atherosclerotic rabbits independently of its lipid-lowering effects. Planta Med. 2013;79:731–736.
   PubMed Web of Science ®Google Scholar
• Ding L, Liang XG, Zhu DY, et al. Icariin promotes expression of PGC-1alpha, PPARalpha, and NRF-1 during cardiomyocyte differentiation of murine embryonic stem cells in vitro. Acta Pharmacol Sin. 2007;28:1541–1549.
   PubMed Web of Science ®Google Scholar
• Lu YF, Xu YY, Jin F, et al. Icariin is a PPARalpha activator inducing lipid metabolic gene expression in mice. Molecules. 2014;19:18179–18191.
   PubMed Web of Science ®Google Scholar
• Dreyer C, Krey G, Keller H, et al. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 1992;68:879–887.
   PubMed Web of Science ®Google Scholar
• Krey G, Braissant O, L’Horset F, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 1997;11:779–791.
   PubMed Web of Science ®Google Scholar
• Xu HE, Lambert MH, Montana VG, et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell. 1999;3:397–403.
   PubMed Web of Science ®Google Scholar
• Holst D, Luquet S, Nogueira V, et al. Nutritional regulation and role of peroxisome proliferator-activated receptor delta in fatty acid catabolism in skeletal muscle. Biochim Biophys Acta. 2003;1633:43–50.
   PubMed Web of Science ®Google Scholar
• Russell AP, Hesselink MK, Lo SK, et al. Regulation of metabolic transcriptional co-activators and transcription factors with acute exercise. FASEB J. 2005;19:986–988.
   PubMed Web of Science ®Google Scholar
• Liu S, Hatano B, Zhao M, et al. Role of peroxisome proliferator-activated receptor {delta}/{beta} in hepatic metabolic regulation. J Biol Chem. 2011;286:1237–1247.
   PubMed Web of Science ®Google Scholar
• Nadra K, Anghel SI, Joye E, et al. Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. Mol Cell Biol. 2006;26:3266–3281.
   PubMed Web of Science ®Google Scholar
• Barak Y, Liao D, He W, et al. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA. 2002;99:303–308.
   PubMed Web of Science ®Google Scholar
• Peters JM, Lee SS, Li W, et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol. 2000;20:5119–5128.
   PubMed Web of Science ®Google Scholar
• Luquet S, Lopez-Soriano J, Holst D, et al. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J. 2003;17:2299–2301.
   PubMed Web of Science ®Google Scholar
• Wang YX, Zhang CL, Yu RT, et al. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol. 2004;2:e294.
   PubMed Web of Science ®Google Scholar
• Schuler M, Ali F, Chambon C, et al. PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab. 2006;4:407–414.
   PubMed Web of Science ®Google Scholar
• Geiger LE, Dunsford WS, Lewis DJ. Rat carcinogenicity study with GW501516, a PPAR delta agonist. Soc Toxicol. 2009;108:895.
   Google Scholar
• Kostadinova R, Montagner A, Gouranton E, et al. GW501516-activated PPARbeta/delta promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation. Cell Biosci. 2012;2:34.
   PubMed Web of Science ®Google Scholar
• Iwaisako K, Haimerl M, Paik YH, et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptor delta agonist. Proc Natl Acad Sci USA. 2012;109:e1369–76.
   PubMed Web of Science ®Google Scholar
• Cho SY, Jeong HW, Sohn JH, et al. An ethanol extract of Artemisia iwayomogi activates PPARdelta leading to activation of fatty acid oxidation in skeletal muscle. PLoS One. 2012;7:e33815.
   PubMed Web of Science ®Google Scholar
• Toral M, Gomez-Guzman M, Jimenez R, et al. Chronic peroxisome proliferator-activated receptorbeta/delta agonist GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity. J Hypertens. 2015;33:1831–1844.
   PubMed Web of Science ®Google Scholar
• Pang M, de la Monte SM, Longato L, et al. PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J Hepatol. 2009;50:1192–1201.
   PubMed Web of Science ®Google Scholar
• Zhao S, Kanno Y, Li W, et al. Picrasidine N is a subtype-selective PPARbeta/delta agonist. J Nat Prod. 2016;79:879–885.
   PubMed Web of Science ®Google Scholar
• Bays HE, Schwartz S, Littlejohn T, et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab. 2011;96:2889–2897.
   PubMed Web of Science ®Google Scholar
• Grewal AS, Beniwal M, Pandita D, et al. Recent updates on peroxisome proliferator-activated receptor delta agonists for the treatment of metabolic syndrome. Med Chem. 2016;12:3–21.
   PubMed Web of Science ®Google Scholar
• Mei YQ, Pan ZF, Chen WT, et al. A flavonoid compound promotes neuronal differentiation of embryonic stem cells via PPAR-beta modulating mitochondrial energy metabolism. PLoS One. 2016;11:e0157747.
   PubMed Web of Science ®Google Scholar
• Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab. 2012;23:351–363.
   PubMed Web of Science ®Google Scholar
• Barak Y, Nelson MC, Ong ES, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell. 1999;4:585–595.
   PubMed Web of Science ®Google Scholar
• Jones JR, Barrick C, Kim KA, et al. Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc Natl Acad Sci USA. 2005;102:6207–6212.
   PubMed Web of Science ®Google Scholar
• Imai T, Takakuwa R, Marchand S, et al. Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse. Proc Natl Acad Sci USA. 2004;101:4543–4547.
   PubMed Web of Science ®Google Scholar
• Wang L, Waltenberger B, Pferschy-Wenzig EM, et al. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARgamma): a review. Biochem Pharmacol. 2014;92:73–89.
   PubMed Web of Science ®Google Scholar
• Weidner C, Wowro SJ, Freiwald A, et al. Amorfrutin B is an efficient natural peroxisome proliferator-activated receptor gamma (PPARgamma) agonist with potent glucose-lowering properties. Diabetologia. 2013;56:1802–1812.
   PubMed Web of Science ®Google Scholar
• Hsu WH, Lee BH, Chang YY, et al. A novel natural Nrf2 activator with PPARgamma-agonist (monascin) attenuates the toxicity of methylglyoxal and hyperglycemia. Toxicol Appl Pharmacol. 2013;272:842–851.
   PubMed Web of Science ®Google Scholar
• Festa C, Lauro G, De Marino S, et al. Plakilactones from the marine sponge Plakinastrella mamillaris. Discovery of a new class of marine ligands of peroxisome proliferator-activated receptor gamma. J Med Chem. 2012;55:8303–8317.
   PubMed Web of Science ®Google Scholar
• Hsu WH, Pan TM. Treatment of metabolic syndrome with ankaflavin, a secondary metabolite isolated from the edible fungus Monascus spp. Appl Microbiol Biotechnol. 2014;98:4853–4863.
   PubMed Web of Science ®Google Scholar
• Lee W, Yoon G, Kim MC, et al. 5,7-Dihydroxy-6-geranylflavanone improves insulin sensitivity through PPARalpha/gamma dual activation. Int J Mol Med. 2016;37:1397–1404.
   PubMed Web of Science ®Google Scholar
• Goto T, Nakayama R, Yamanaka M, et al. Effects of DSP-8658, a novel selective peroxisome proliferator-activated receptors a/gamma modulator, on adipogenesis and glucose metabolism in diabetic obese mice. Exp Clin Endocrinol Diabetes. 2015;123:492–499.
   PubMed Web of Science ®Google Scholar
• Ge J, Miao JJ, Sun XY, et al. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-alpha/gamma and attenuating endoplasmic reticulum stress in rats. J Ethnopharmacol. 2016;189:238–249.
   PubMed Web of Science ®Google Scholar
• Park MH, Kim DH, Kim MJ, et al. Effects of MHY908, a new synthetic PPARalpha/gamma dual agonist, on inflammatory responses and insulin resistance in aged rats. J Gerontol A Biol Sci Med Sci. 2016;71:300–309.
   PubMed Web of Science ®Google Scholar
• Qi ZG, Zhao X, Zhong W, et al. Osthole improves glucose and lipid metabolism via modulation of PPARalpha/gamma-mediated target gene expression in liver, adipose tissue, and skeletal muscle in fatty liver rats. Pharm Biol. 2016;54:882–888.
   PubMed Web of Science ®Google Scholar
• Gilardi F, Giudici M, Mitro N, et al. LT175 is a novel PPARalpha/gamma ligand with potent insulin-sensitizing effects and reduced adipogenic properties. J Biol Chem. 2014;289:6908–6920.
   PubMed Web of Science ®Google Scholar
• Zang C, Liu H, Waechter M, et al. Dual PPARalpha/gamma ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines. Cell Cycle. 2006;5:2237–2243.
   PubMed Web of Science ®Google Scholar
• Kim JW, Kim JR, Yi S, et al. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-gamma agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects. Clin Ther. 2011;33:1819–1830.
   PubMed Web of Science ®Google Scholar
• Jani RH, Pai V, Jha P, et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther. 2014;16:63–71.
   PubMed Web of Science ®Google Scholar
• Jain MR, Giri SR, Trivedi C, et al. Saroglitazar, a novel PPARalpha/gamma agonist with predominant PPARalpha activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. Pharmacol Res Perspect. 2015;3:e00136.
   PubMed Web of Science ®Google Scholar
• Matsuura N, Gamo K, Miyachi H, et al. Gamma-mangostin from Garcinia mangostana pericarps as a dual agonist that activates both PPARalpha and PPARdelta. Biosci Biotechnol Biochem. 2013;77:2430–2435.
   PubMed Web of Science ®Google Scholar
• Hanf R, Millatt LJ, Cariou B, et al. The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects. Diab Vasc Dis Res. 2014;11:440–447.
   PubMed Web of Science ®Google Scholar
• Bassaganya-Riera J, DiGuardo M, Climent M, et al. Activation of PPARgamma and delta by dietary punicic acid ameliorates intestinal inflammation in mice. Br J Nutr. 2011;106:878–886.
   PubMed Web of Science ®Google Scholar
• Lee JH, Noh CK, Yim CS, et al. Kinetics of the absorption, distribution, metabolism, and excretion of lobeglitazone, a novel activator of peroxisome proliferator-activated receptor gamma in rats. J Pharm Sci. 2015;104:3049–3059.
   PubMed Web of Science ®Google Scholar
• Jin SM, Park CY, Cho YM, et al. Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension. Diabetes Obes Metab. 2015;17:599–602.
   PubMed Web of Science ®Google Scholar
• Agrawal R. The first approved agent in the Glitazar’s class: saroglitazar. Curr Drug Targets. 2014;15:151–155.
   PubMed Web of Science ®Google Scholar
• Guo Q, Sahoo SP, Wang PR, et al. A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology. 2004;145:1640–1648.
   PubMed Web of Science ®Google Scholar
• Zang C, Liu H, Bertz J, et al. Induction of endoplasmic reticulum stress response by TZD18, a novel dual ligand for peroxisome proliferator-activated receptor alpha/gamma, in human breast cancer cells. Mol Cancer Ther. 2009;8:2296–2307.
   PubMed Web of Science ®Google Scholar
• Park MH, Park JY, Lee HJ, et al. Potent anti-diabetic effects of MHY908, a newly synthesized PPAR alpha/gamma dual agonist in db/db mice. PLoS One. 2013;8:e78815.
   PubMed Web of Science ®Google Scholar
• Nam HH, Jun DW, Jeon HJ, et al. Osthol attenuates hepatic steatosis via decreased triglyceride synthesis not by insulin resistance. World J Gastroenterol. 2014;20:11753–11761.
   PubMed Web of Science ®Google Scholar
• Zhao X, Xue J, Wang XL, et al. Involvement of hepatic peroxisome proliferator-activated receptor alpha/gamma in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats. Int Immunopharmacol. 2014;22:176–181.
   PubMed Web of Science ®Google Scholar
• Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013;58:1941–1952.
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu X, Xie XB, et al. Multitargeted bioactive ligands for PPARs discovered in the last decade. Chem Biol Drug Des. 2016;88:635–663.
   PubMed Web of Science ®Google Scholar
• Matin A, Doddareddy MR, Gavande N, et al. The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists. Bioorg Med Chem. 2013;21:766–778.
   PubMed Web of Science ®Google Scholar
• Feng L, Luo H, Xu Z, et al. Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-gamma and PPAR-alpha agonists on carbohydrate and lipid metabolism in db/db and diet-induced obese mice. Diabetologia. 2016;59:1276–1286.
   PubMed Web of Science ®Google Scholar
• Sadasivuni MK, Reddy BM, Singh J, et al. CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models. Diabetol Metab Syndr. 2014;6:83.
   PubMed Web of Science ®Google Scholar
• Harrington WW, Britt C S, Wilson J G, et al. The effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan agonists on body weight, body mass, and serum lipid profiles in diet-induced obese AKR/J mice. PPAR Res. 2007;2007:97125.
   PubMed Web of Science ®Google Scholar
• Santin JR, Daufenback Machado I, Rodrigues SF, et al. Role of an indole-thiazolidine molecule PPAR pan-agonist and COX inhibitor on inflammation and microcirculatory damage in acute gastric lesions. PLoS One. 2013;8:e76894.
   PubMed Web of Science ®Google Scholar
• Chen W, Fan S, Xie X, et al. Novel PPAR pan agonist, ZBH ameliorates hyperlipidemia and insulin resistance in high fat diet induced hyperlipidemic hamster. PLoS One. 2014;9:e96056.
   PubMed Web of Science ®Google Scholar
• Ruzehaji N, Frantz C, Ponsoye M, et al. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. Ann Rheum Dis. 2016;75:2175–2183.
   PubMed Web of Science ®Google Scholar
• Vigerust NF, Cacabelos D, Burri L, et al. Fish oil and 3-thia fatty acid have additive effects on lipid metabolism but antagonistic effects on oxidative damage when fed to rats for 50 weeks. J Nutr Biochem. 2012;23:1384–1393.
   PubMed Web of Science ®Google Scholar
• Bjorndal B, Grimstad T, Cacabelos D, et al. Tetradecylthioacetic acid attenuates inflammation and has antioxidative potential during experimental colitis in rats. Dig Dis Sci. 2013;58:97–106.
   PubMed Web of Science ®Google Scholar
• Penna-de-Carvalho A, Graus-Nunes F, Rabelo-Andrade J, et al. Enhanced pan-peroxisome proliferator-activated receptor gene and protein expression in adipose tissue of diet-induced obese mice treated with telmisartan. Exp Physiol. 2014;99:1663–1678.
   PubMed Web of Science ®Google Scholar
• Ament Z, West JA, Stanley E, et al. PPAR-pan activation induces hepatic oxidative stress and lipidomic remodelling. Free Radic Biol Med. 2016;95:357–368.
   PubMed Web of Science ®Google Scholar
• Thao NP, Luyen BT, Ngan NT, et al. Peroxisome proliferator-activated receptor transactivational effects in HepG2 cells of cembranoids from the soft coral Lobophytum crassum Von Marenzeller. Arch Pharm Res. 2015;38:769–775.
   PubMed Web of Science ®Google Scholar
• Schug TT, Berry DC, Shaw NS, et al. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell. 2007;129:723–733.
   PubMed Web of Science ®Google Scholar
• Tan NS, Shaw NS, Vinckenbosch N, et al. Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol. 2002;22:5114–5127.
   PubMed Web of Science ®Google Scholar
• Rieck M, Meissner W, Ries S, et al. Ligand-mediated regulation of peroxisome proliferator-activated receptor (PPAR) beta/delta: a comparative analysis of PPAR-selective agonists and all-trans retinoic acid. Mol Pharmacol. 2008;74:1269–1277.
   PubMed Web of Science ®Google Scholar
• Zhang H, Xu X, Chen L, et al. Molecular determinants of magnolol targeting both RXRalpha and PPARgamma. PLoS One. 2011;6:e28253.
   PubMed Web of Science ®Google Scholar
• Atanasov AG, Wang JN, Gu SP, et al. Honokiol: a non-adipogenic PPARgamma agonist from nature. Biochim Biophys Acta. 2013;1830:4813–4819.
   PubMed Web of Science ®Google Scholar
• Grimaldi M, Boulahtouf A, Delfosse V, et al. Reporter cell lines for the characterization of the interactions between human nuclear receptors and endocrine disruptors. Front Endocrinol Lausanne. 2015;6:62.
   PubMed Web of Science ®Google Scholar
• Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645–650.
   PubMed Web of Science ®Google Scholar
• Fujita T, Sugiyama Y, Taketomi S, et al. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes. 1983;32:804–810.
   PubMed Web of Science ®Google Scholar
• Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270:12953–12956.
   PubMed Web of Science ®Google Scholar
• Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088–2093.
   PubMed Web of Science ®Google Scholar
• Montagner A, Korecka A, Polizzi A, et al. Hepatic circadian clock oscillators and nuclear receptors integrate microbiome-derived signals. Sci Rep. 2016;6:20127.
   PubMed Web of Science ®Google Scholar
• Staniek A, Bouwmeester H, Fraser PD, et al. Natural products - learning chemistry from plants. Biotechnol J. 2014;9:326–336.
   PubMed Web of Science ®Google Scholar
• Rubenstrunk A, Hanf R, Hum DW, et al. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta. 2007;1771:1065–1081.
   PubMed Web of Science ®Google Scholar